Evaluation of Myocardial Reperfusion After Primary PCI in Patients With High Platelet Reactivity Treated by Cangrelor or Not

• Status: Recruiting
• Trial end date: 2023-01-01
• Target enrollment: 0
• Participant gender: All

Summary

This study aims to evaluate the impact on myocardial reperfusion and residual thrombotic burden of adding Cangrelor -a potent and immediate P2Y12 inhibitor- to ticagrelor in primary PCI patients with high on ticagrelor platelet reactivity compared to standard of care with ticagrelor alone.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University Hospital, Caen
• Collaborator: Terumo Medical Corporation
• Treatments: Cangrelor

Criteria

Inclusion Criteria:

• patient admitted for STEMI within 24 hours from symptom onset

• pretreated with ticagrelor, aspirin and enoxaparin (according local protocol)

• successfully treated by primary PCI of a native coronary culprit lesion

• anatomy accessible to optical coherence tomography (OCT or OFDI)

Exclusion Criteria:

• cardiogenic shock

• stent restenosis or thrombosis

• use of glycoprotein IIb/IIIa inhibitors before or during PCI

• known coagulation disease

• high bleeding risk (thrombocytopenia <100,000/dL, surgery <30 days, active bleeding)

• uncontrolled arterial hypertension (>180/110 mmHg)

• history of stroke (ischemic or hemorrhagic) or transient ischemic attack

• known severe renal insufficiency (eGFR <30 ml/min)

• oral anticoagulation